Disease Landscape and Forecast Insights

The increasing rates of resistance to antibiotics among gram-negative pathogens have driven the development of antibiotics that target specific mechanisms of resistance and/or bacterial species…

Market Outlook Carbapenem-resistant organisms (CROs) are responsible for difficult-to-treat, life-threatening gram-negative infections that require hospitalization. Of the currently marketed…

MARKET OUTLOOK Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with these agents…

ACS is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Current drug targets for ACS, particularly those in the acute…

In an attempt to mitigate postoperative pain following surgical procedures, patients may be administered analgesics/anesthetics intraoperatively, postoperatively, and at hospital discharge. Opioids…

The relatively recent FDA approvals of tedizolid (Merck’s Sivextro), dalbavancin (Allergan’s Dalvance), and oritavancin (The Medicines Company’s Orbactiv) for the treatment of acute bacterial…

Gram-negative infections (GNIs) account for a large portion of hospital-treated infections (HTIs), which represent a high-value segment of the antibacterial market given the severity of these…

Due to rising antimicrobial resistance (AMR) rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs…

Acute heart failure (AHF) is one of the leading causes of hospitalization in the United States, representing a significant healthcare burden. AHF patients experience high rates of mortality and…

The hospital-treated gram-negative infection (GNI) market is dominated by highly effective, generically available antibiotics. However, the rising prevalence of multidrug-resistant (MDR) pathogens…

Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The newly marketed oritavancin (The Medicine…

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-positive infections (GPIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…